ClearPoint Neuro, Inc.

NASDAQ:CLPT

Medical - Devices

Healthcare
$7.71 +5.30%

+$0.89 today

Market cap
$247.14M
Beta
1.31
P/E (TTM)
-18.0
EPS (TTM)
-$0.98
52W Low $8.27High $30.10

Volume 0.64M

Average 0.67M

CLPT EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

ClearPoint Neuro, Inc.NASDAQ: CLPT

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$7.05M, compared with -$5.67M a year earlier. Trailing-twelve-month EBITDA was -$23.66M.

Context

  • EBITDA amounted to 56.4% of revenue in FY2025, up 2.2 pp from a year earlier.
  • EBITDA grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 1 analysts of -$30.26M (-45.0%) for the fiscal year ending Dec 2026, a slowdown from the -22.6% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$7.05M-13.2% QoQ
Last fiscal yearDec 2025
-$20.86M-22.6% YoY
LTMMar 2026
-$23.66M-24.4% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-24.2%-19.4%+4.9 pp
1 year-22.6%-45.0%-22.4 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(20.86M) USD
Year-over-year change
-22.6%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How CLPT compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -24.4% is the 6th highest of 10, against a peer median of +5.7%.
  • EBITDA amounts to 58.2% of revenue for CLPT, versus a peer median of 4.1%.
CLPT Competitors
EBITDA for CLPT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OFIXOrthofix Medical Inc.LTM Mar 2026$94.51M USD+693.8%—11.5%
SNDLSNDL Inc.LTM Mar 2026CA$49.42M CAD+201.3%—5.3%
AKBAAkebia Therapeutics, Inc.LTM Mar 2026-$5.76M USD-220.1%+92.3%2.5%
SIBNSI-BONE, Inc.LTM Mar 2026-$5.99M USD+68.1%—2.9%
VREXVarex Imaging CorporationLTM Apr 2026-$6.2M USD-108.2%-68.7%0.7%
AVNSAvanos Medical, Inc.LTM Mar 2026-$21.6M USD+93.7%—3.0%
CTKBCytek Biosciences, Inc.LTM Mar 2026-$22.15M USD-84.1%—10.8%
CLPTClearPoint Neuro, Inc.LTM Mar 2026-$23.66M USD-24.4%—58.2%
LABStandard BioTools Inc.LTM Mar 2026-$81.51M USD+5.7%—94.5%
CMPSCOMPASS Pathways plcLTM Mar 2026-$176.6M USD-34.4%——
Peer median (excluding CLPT) —+5.7%+11.8%4.1%

Competitors are the stored peer set for CLPT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue16.3M20.55M23.96M31.39M36.97M
Cost of Revenue5.18M7.02M10.34M12.27M14.28M
Gross Profit11.12M13.53M13.61M19.12M22.69M
Gross Margin68.2%65.8%56.8%60.9%61.4%
Research & Development9.28M10.89M11.71M12.39M13.9M
Selling, General & Admin15.22M18.97M24.35M26.48M32.96M
Operating Expenses24.5M29.86M36.06M38.87M46.86M
Depreciation & Amortization692K777K1.46M1.9M2.24M
EBITDA(12.75M)(15.58M)(20.63M)(17.01M)(20.86M)
EBITDA Margin-78.2%-75.8%-86.1%-54.2%-56.4%
Operating Income(13.37M)(16.33M)(22.45M)(19.75M)(24.16M)
Operating Margin-82.1%-79.5%-93.7%-62.9%-65.4%
Interest Income00386K872K1.21M
Interest Expense973K81K002.39M
Other Income / Expenses(1.04M)(103K)357K832K(1.32M)
Income Before Tax(14.41M)(16.44M)(22.09M)(18.91M)(25.49M)
Pre-Tax Margin-88.4%-80.0%-92.2%-60.3%-68.9%
Income Tax Expense000055K
Net Income(14.41M)(16.44M)(22.09M)(18.91M)(25.54M)
Net Margin-88.4%-80.0%-92.2%-60.3%-69.1%
EPS (Basic)(0.69)(0.68)(0.90)(0.70)(0.90)
EPS (Diluted)(0.69)(0.68)(0.90)(0.70)(0.90)
Weighted Avg Shares20.73M24.18M24.61M27.03M28.32M
Weighted Avg Shares (Diluted)20.73M24.18M24.61M27.03M28.32M

ClearPoint Neuro, Inc.

NASDAQ:CLPT

Intrinsic Alpha fair value

Locked

Current Price

$7.71

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.